Elanco Animal Health (ELAN) Net Income towards Common Stockholders (2017 - 2026)

Elanco Animal Health has disclosed Net Income towards Common Stockholders across 10 years of filings, most recently posting $54.0 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders rose 390.91% year-over-year to $54.0 million; the TTM figure through Jun 2026 stood at -$199.0 million (down 145.85% YoY), while the FY2025 annual figure was -$232.0 million, down 168.64% from the prior year.
• Net Income towards Common Stockholders came in at $54.0 million for Q2 2026 at Elanco Animal Health, down from $57.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $364.0 million in Q3 2024 to a low of -$1.1 billion in Q3 2023.
• Average Net Income towards Common Stockholders over 5 years is -$60.7 million, with a median of -$9.0 million recorded in 2022.
• Year-over-year, Net Income towards Common Stockholders plunged 3350.0% in 2025 and jumped 390.91% in 2026.
• Over 5 years, Net Income towards Common Stockholders stood at -$54.0 million in 2022, then plunged by 161.11% to -$141.0 million in 2023, then jumped by 94.33% to -$8.0 million in 2024, then sank by 3350.0% to -$276.0 million in 2025, then jumped by 119.57% to $54.0 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $54.0 million in Q2 2026, $57.0 million in Q1 2026, and -$276.0 million in Q4 2025.